The study recently announced by PExA AB (publ), in which researchers demonstrated that virus-specific antibodies from the lungs’ small airways can be analyzed non-invasively using the company’s technology, is now also featured on the cover of the November issue of eBioMedicine. The journal is internationally recognized as a leading publication in biomedicine, is part of…
Read moreA new scientific study by researchers at Karolinska Institutet, Danderyd Hospital and Uppsala University demonstrates that samples collected non-invasively using PExA can be used to measure virus-specific antibodies from the small airways. Published in eBioMedicine, one of the leading international scientific journals in biomedicine and part of The Lancet Discovery Science, the study opens new…
Read moreAn Australian study shows that PExA’s non-invasive lung sampling technology captures hundreds of proteins also found through invasive bronchoalveolar lavage (BAL)—a resource-intensive procedure involving patient burden and procedural risks. The findings provide strong support for PExA’s ability to capture biologically relevant molecular information from the small airways. The company regards the study as a major…
Read morePExA AB (publ) has been granted a European patent that strengthens the company’s intellectual property protection in the field of mechanical ventilation. At the same time, the company has received positive patent decisions in both Europe and China concerning a sample preparation technology. These developments strengthen PExA’s international patent portfolio, which covers both the company’s…
Read morePExA AB has recently completed the installation and training of a second PExA 2.1 system ordered by the German Federal Institute for Occupational Safety and Health, Bundesanstalt für Arbeitsschutz und Arbeitsmedizin (BAuA). The system was installed at the end of September in the pulmonary function unit at Universitätsmedizin Greifswald and is now in place and…
Read more
